Ryvu Therapeutics SA (WAR:RVU) — Market Cap & Net Worth
Market Cap & Net Worth: Ryvu Therapeutics SA (RVU)
Ryvu Therapeutics SA (WAR:RVU) has a market capitalization of $93.79 Million (zł340.79 Million) as of August 1, 2026. Listed on the WAR stock exchange, this Poland-based company holds position #19360 globally and #154 in its home market, demonstrating a -2.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ryvu Therapeutics SA's stock price zł14.74 by its total outstanding shares 23120148 (23.12 Million). See reinvestment intensity of Ryvu Therapeutics SA to understand how much of operating cash flow is reinvested back into capital assets.
Ryvu Therapeutics SA Market Cap History: 2015 to 2026
Ryvu Therapeutics SA's market capitalization history from 2015 to 2026. Data shows growth from $87.99 Million to $93.79 Million (0.59% CAGR).
Ryvu Therapeutics SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ryvu Therapeutics SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.77x
Ryvu Therapeutics SA's market cap is 2.77 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $121.16 Million | $48.13 Million | $2.72 Million | 2.52x | 44.54x |
| 2017 | $243.24 Million | $87.82 Million | $6.41 Million | 2.77x | 37.97x |
| 2018 | $225.63 Million | $77.21 Million | -$106.32K | 2.92x | N/A |
| 2019 | $286.33 Million | $42.57 Million | -$36.00 Million | 6.73x | N/A |
| 2020 | $313.06 Million | $15.41 Million | -$31.69 Million | 20.31x | N/A |
| 2021 | $388.14 Million | $11.19 Million | -$79.08 Million | 34.70x | N/A |
| 2022 | $313.38 Million | $38.80 Million | -$83.78 Million | 8.08x | N/A |
| 2023 | $365.87 Million | $46.86 Million | -$92.11 Million | 7.81x | N/A |
| 2024 | $244.98 Million | $77.97 Million | -$111.44 Million | 3.14x | N/A |
| 2025 | $172.44 Million | $62.25 Million | -$101.23 Million | 2.77x | N/A |
Competitor Companies of RVU by Market Capitalization
Companies near Ryvu Therapeutics SA in the global market cap rankings as of August 1, 2026.
Key companies related to Ryvu Therapeutics SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Ryvu Therapeutics SA Historical Marketcap From 2015 to 2026
Between 2015 and today, Ryvu Therapeutics SA's market cap moved from $87.99 Million to $ 93.79 Million, with a yearly change of 0.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | zł93.79 Million | -45.61% |
| 2025 | zł172.44 Million | -29.61% |
| 2024 | zł244.98 Million | -33.04% |
| 2023 | zł365.87 Million | +16.75% |
| 2022 | zł313.38 Million | -19.26% |
| 2021 | zł388.14 Million | +23.98% |
| 2020 | zł313.06 Million | +9.33% |
| 2019 | zł286.33 Million | +26.91% |
| 2018 | zł225.63 Million | -7.24% |
| 2017 | zł243.24 Million | +100.76% |
| 2016 | zł121.16 Million | +37.70% |
| 2015 | zł87.99 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Ryvu Therapeutics SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $93.79 Million USD |
| MoneyControl | $93.79 Million USD |
| MarketWatch | $93.79 Million USD |
| marketcap.company | $93.79 Million USD |
| Reuters | $93.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ryvu Therapeutics SA
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myel… Read more